Loading clinical trials...
Loading clinical trials...
A 6-month Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and PK/PD of an age-and Body Weight-adjusted Oral Finerenone Regimen, in Addition to an ACEI or ARB, for the Treatment of Children, 6 Months to <18 Years of Age, With Chronic Kidney Disease and Proteinuria
Conditions
Interventions
Finerenone (Kerendia, BAY94-8862)
Placebo
Locations
164
United States
Phoenix Children's Hospital | Main - Transplant Department
Phoenix, Arizona, United States
Cedars-Sinai Medical Center - Nephrology
Los Angeles, California, United States
Lucille Packard Children's Hospital Stanford - Pediatric Nephrology
Palo Alto, California, United States
UC San Diego - Altman Clinical and Translational Research Institute (ACTRI) - Linda Vista Clinic
San Diego, California, United States
Children's National Hospital - Nephrology
Washington D.C., District of Columbia, United States
Memorial Transplant Institute - Pediatric Nephrology
Hollywood, Florida, United States
Start Date
March 28, 2022
Primary Completion Date
July 31, 2027
Completion Date
August 31, 2027
Last Updated
April 17, 2026
NCT05398783
NCT07547098
NCT00977977
NCT07232537
NCT06721143
NCT06278207
Lead Sponsor
Bayer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions